SDGR - Schrödinger, Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 34.47 |
| Open | 34.46 |
| Bid | 33.47 x 900 |
| Ask | 33.50 x 800 |
| Day's Range | 33.42 - 35.03 |
| 52 Week Range | 15.85 - 40.69 |
| Volume | |
| Avg. Volume | 735,188 |
| Market Cap | 2.391B |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | 257.08 |
| EPS (TTM) | 0.13 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.78 |
Fair Value
Related Research
InvestorPlace3 Pharma Stocks That Will Boom Thanks to AI
A Deloitte report about artificial intelligence (AI) in the life sciences puts it bluntly. Big data is the new currency for biopharma firms. The quantum leap forward in computational power that AI affords gives pharmaceutical firms the ability to develop products faster than ever before. This has lead investors to start looking for the top AI-driven pharma stocks. The intersection of data science and machine learning makes research and development fundamentally different than it was previously.
Business WireSchrödinger to Present at Jefferies Global Biopharma Conference
NEW YORK, May 26, 2023--Schrödinger will participate in a fireside chat at the Jefferies Healthcare Conference.
Business WireSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, May 25, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on May 19, 2023, the company granted (i) non-statutory stock options to purchase 7,660 shares of the company’s common stock to five newly hired employees and (ii) restricted stock units (RSUs) with respect to 1,988 shares of the company’s common stock to two newly hired employees. These grants were made pursuan
Insider MonkeyBill Gates’ Most Recent Portfolio: Top 15 Stock Picks
In this piece, we will look at the top fifteen stock picks in Bill Gates’ most recent portfolio. For more stocks, head on over to Bill Gates’ Most Recent Portfolio: Top 5 Stock Picks. Today’s age is the information age. If you have a smartphone and an internet connection, you can look up vast amounts […]
InvestorPlace3 High-Reward Stocks Riding the AI Boom
A few recent news stories highlight the tremendous power of artificial intelligence to improve our world and boost business performance. A doctor says that the technology can be a key means of enabling healthcare to become more personalized and making diagnoses earlier. Two fast-food chains are using AI “to boost [the] accuracy, speed, and revenue [of their] drive-thru ordering process.” And finally, the technology is giving robots the ability “to learn and make decisions.” These examples show t
InvestorPlace7 Growth Stocks That Could Double Your Money in 2023
While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks. However, if the circumstances hit just right, these ideas can help get your portfolio on the right track quickly. According to ChatGPT, growth-oriented enterprises carry the expectation to grow at a faster rate than the overall market. Typically, we’re talking about 8% for the S&P 500 inde
Motley FoolWhy Investors Should Keep an Eye on These 3 AI Start-Ups, Including UiPath and C3.ai
The future is here, and you can be a cutting-edge investor by plowing money into one or more of these stocks.
InvestorPlaceThe 7 Most Undervalued Growth Stocks for Your May Buy List
With short sellers viciously attacking many popular stocks and Wall Street worrying too much about the macroeconomic outlook, there are a multitude of undervalued growth stocks for investors to buy now. Plus, three recent factors have increased my optimism about growth stocks. One data point was America’s Services PMI for April which climbed to 51.9 from 51.2 in March, showing that services, which drive the U.S. economy, are continuing to expand. Secondly, as of May 4, the Atlanta Federal Reserv
Insider MonkeySchrödinger, Inc. (NASDAQ:SDGR) Q1 2023 Earnings Call Transcript
Schrödinger, Inc. (NASDAQ:SDGR) Q1 2023 Earnings Call Transcript May 4, 2023 Operator: Thank you for standing by. Welcome to Schrodinger’s Conference Call to review First Quarter 2020 Financial Results. My name is Joanna, and I will be your operator for today’s call. Please be advised that this call is being recorded at the company’s request. […]
- Thomson Reuters StreetEvents
Q1 2023 Schrodinger Inc Earnings Call
Q1 2023 Schrodinger Inc Earnings Call
Simply Wall St.Schrödinger, Inc.'s (NASDAQ:SDGR) P/S Still Appears To Be Reasonable
Schrödinger, Inc.'s ( NASDAQ:SDGR ) price-to-sales (or "P/S") ratio of 11.9x may look like a poor investment...
ZacksSchrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -127.94% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireSchrödinger Reports Strong First Quarter 2023 Financial Results
NEW YORK, May 04, 2023--Schrödinger today announced financial results for the first quarter ended March 31, 2023.
Business WireSchrödinger Publishes Inaugural Corporate Sustainability Report
NEW YORK, April 27, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today published its inaugural Corporate Sustainability Report. The report highlights the company's vision and approach to corporate sustainability, summarizes the company’s 2022 achievements and discloses key data about its corporate sustainability efforts in alignment with GRI and SASB reporting standards.
- Business Wire
Schrödinger to Announce First Quarter 2023 Financial Results on May 4
NEW YORK, April 20, 2023--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its first quarter 2023 financial results on Thursday, May 4, 2023, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
InvestorPlaceThe 3 Best AI Stocks to Buy Right Now
Artificial intelligence (AI) is a powerful technology that will enable many businesses to both save money and accelerate growth. As a result, demand for powerful, efficient AI tools is likely to explode, and companies that can deliver them will be quite prosperous. Today, we’ll look at three of the best AI stocks on the market. Expanding on my previous points, an article in The Fast Mode concludes: “AI can help companies save money by automating repetitive tasks, analyzing data, and identifying
- Simply Wall St.
With 80% ownership of the shares, Schrödinger, Inc. (NASDAQ:SDGR) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Schrödinger's stock price might be vulnerable to their...
InvestorPlace3 Tech Stocks to Buy for the Fourth Industrial Revolution
The Fourth Industrial Revolution refers to the use of multiple advanced technologies, including “artificial intelligence (AI), robotics, [and] the Internet of Things (IoT).” Also in the mix are “faster computer processing,” “biotechnology,” and “Energy capture, storage, and transmission,” Salesforce reported. I’m upbeat about all of those technologies, and I advise investors to find tech stocks to buy that are each a play on at least two of these innovations. Certainly, AI-powered robotics are a
Motley FoolNot Quite a Bailout: So Much Banking News to Discuss
How big banks like JPMorgan Chase and Bank of America are gaining strength simply by going about their business. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center.
InvestorPlace3 Amazing AI Stocks for Your March Buy List
The Street is realizing what computer scientists and many observers have known for years: artificial intelligence has become tremendously powerful and will have a huge impact on our lives. Moreover, AI enables companies to perform tremendously valuable services for each other and consumers. Consequently, companies with outstanding, well-developed AI technology will become very profitable, making these firms and their AI stocks wonderful investments. Healthcare and IT are the two areas in which A
Motley FoolWhy Shares of Schrödinger Were Up Today
Shares of Schrödinger (NASDAQ: SDGR) rose by more than 20% on Wednesday morning after the healthcare company released its fourth-quarter and annual reports following the close of trading on Tuesday. The company provides molecular simulations and software solutions and services for pharmaceutical, biotechnology, and materials science research. The company reported fourth-quarter revenue of $56.8 million, up 23% year over year, and a net loss for the quarter of $27.2 million, compared to a $30.7 million net loss in the prior-year period.
- Thomson Reuters StreetEvents
Q4 2022 Schrodinger Inc Earnings Call
Q4 2022 Schrodinger Inc Earnings Call
ZacksSchrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Schrödinger Reports Strong Fourth Quarter and Full-Year 2022 Financial Results
NEW YORK, February 28, 2023--Schrödinger today reported fourth quarter and full-year 2022 financial results.
- Business Wire
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
NEW YORK, February 14, 2023--Schrödinger Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported the receipt of an $111.3 million cash distribution from Nimbus Therapeutics, LLC (Nimbus) in connection with Takeda’s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858 is being evaluated for the treatment of multiple autoim